

May 7, 2007



## **XOMA Executives to Present at BIO2007 Convention, Rodman & Renshaw Global Healthcare, Needham Biotechnology and Jefferies Healthcare Conferences**

BERKELEY, Calif., May 7, 2007 (PRIME NEWSWIRE) -- Executives from XOMA Ltd. (Nasdaq:XOMA), a therapeutic antibody discovery and product development company, will be presenting at four upcoming industry and financial meetings, discussing the company's proprietary technologies, business strategy and clinical progress.

Patricia Donahue, senior director business development, will present at the BIO2007 Convention Business Forum in Boston at 9:30 am on Tuesday, May 8th.

Dave Boyle, vice president finance and chief financial officer, will present at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday, May 15 at 9:45 am. A webcast can be accessed at:

<http://www.wsw.com/webcast/rrshq11/xoma>

XOMA will also present at the Sixth Annual Needham & Company, LLC Biotechnology and Medical Technology Conference June 13-14, and at the Jefferies Healthcare Conference, June 26-28, both in New York. Further details about these presentations will be posted at the XOMA web site [www.xoma.com](http://www.xoma.com) before the events.

### About XOMA

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.

The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(HE) and Bacterial Cell Expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc.; Novartis; Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at [www.xoma.com](http://www.xoma.com).

Certain statements contained herein concerning current collaborations and product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of pre-clinical testing, the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data), changes in the status of the existing collaborative relationships, the ability of collaborators and other partners to meet their obligations, market demand for products, scale up and marketing capabilities, competition, share price volatility, XOMA's financing needs and opportunities, uncertainties regarding the status of biotechnology patents, uncertainties as to the cost of protecting intellectual property and risks associated with XOMA's status as a Bermuda company, are described in more detail in the Company's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

CONTACT: XOMA Ltd.  
J. David Boyle II, Vice President Finance,  
Chief Financial Officer  
(510) 204-7200  
[investorrelations@xoma.com](mailto:investorrelations@xoma.com)  
[www.xoma.com](http://www.xoma.com)